Drug therapy for atrial fibrillation: What will its role be in the era of increasing use of catheter ablation?

PACE - Pacing and Clinical Electrophysiology

Volumn 32, Issue 1, 2009, Pages 108-118

  Morrow, John P ^a   Reiffel, James A ^a,b  

^a Columbia University ^*  (United States)

^b NONE   (United States)

Author keywords

Atrial fibrillation; Clinical trials; Pharmacology

Indexed keywords

2 [7 [3 (4 CYANOPHENOXY) 2 HYDROXYPROPYL] 9 OXA 3,7 DIAZABICYCLO[3.3.1]NON 3 YL]ETHYLCARBAMIC ACID TERT BUTYL ESTER; 2 ISOPROPYLIDENEHYDRAZONO 4 OXO 5 THIAZOLIDINYLACETANILIDE; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTIHYPERTENSIVE AGENT; ATI 2042; AZIMILIDE; CELIVARONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOFETILIDE; DRONEDARONE; ENALAPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ION CHANNEL; IRBESARTAN; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ANTAGONIST; PIRFENIDONE; PLACEBO; RANOLAZINE; ROTIGAPTIDE; SEROTONIN; SOTALOL; STEROID; UNCLASSIFIED DRUG; VERNAKALANT;

ABNORMAL TASTE; ACTION POTENTIAL; ACUTE CORONARY SYNDROME; ATRIOVENTRICULAR BLOCK; CARDIOGENIC SHOCK; CATHETER ABLATION; CLINICAL TRIAL; DISEASE RESISTANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EYE TOXICITY; FIBROSIS; GAP JUNCTION; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART PROARRHYTHMIA; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; HYPOTENSION; LUNG TOXICITY; MONOTHERAPY; NONHUMAN; RECURRENT DISEASE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; SINUS RHYTHM; SNEEZING; TASTE; THYROID TOXICITY; TORSADE DES POINTES; TOXICITY;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CATHETER ABLATION; COMBINED MODALITY THERAPY; FORECASTING; HUMANS; PHYSICIAN'S PRACTICE PATTERNS;

EID: 58149267837     PISSN: 01478389     EISSN: 15408159     Source Type: Journal    
DOI: 10.1111/j.1540-8159.2009.02184.x     Document Type: Review

References (78)

1. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA 2001 285 : 2370 2375.
2. Reiffel J. The AFFECTS Registry Steering Committee and Investigators. The selection of a rate versus rhythm control strategy for atrial fibrillation management following AFFIRM and RACE 2007.
3. Ruskin JN. The cardiac arrhythmia suppression trial (CAST). N Engl J Med 1989 321 : 386 388.
4. Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF, Pitt B, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival with Oral d-Sotalol. Lancet 1996 348 : 7 12.
5. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002 347 : 1825 1833.
6. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, Said SA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002 347 : 1834 1840.
7. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF): A randomised trial. Lancet 2000 356 : 1789 1794.
8. Carlsson J, Miketic S, Windeler J, Cuneo A, Haun S, Micus S, Walter S, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: The Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 2003 41 : 1690 1696.
9. Pedersen OD, Bagger H, Keller N, Marchant B, Kober L, Torp-Pedersen C. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: A Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation 2001 104 : 292 296.
10. Corley SD, Epstein AE, DiMarco JP, Domanski MJ, Geller N, Greene HL, Josephson RA, et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 2004 109 : 1509 1513.
11. XIII World Congress on Cardiac Pacing and Electrophysiology. Rome, Italy 2007.
12. Wazni OM, Marrouche NF, Martin DO, Verma A, Bhargava M, Saliba W, Bash D, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: A randomized trial. JAMA 2005 293 : 2634 2640.
13. Pappone C, Augello G, Sala S, Gugliotta F, Vicedomini G, Gulletta S, Paglino G, et al. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: The APAF Study. J Am Coll Cardiol 2006 48 : 2340 2347.
14. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995 92 : 1954 1968.
15. Weber KT, Brilla CG, Janicki JS. Myocardial fibrosis: Functional significance and regulatory factors. Cardiovasc Res 1993 27 : 341 348.
16. Kato H, Suzuki H, Tajima S, Ogata Y, Tominaga T, Sato A, Saruta T. Angiotensin II stimulates collagen synthesis in cultured vascular smooth muscle cells. J Hypertens 1991 9 : 17 22.
17. Sugden PH, Clerk A. Cellular mechanisms of cardiac hypertrophy. J Mol Med 1998 76 : 725 746.
18. Nakashima H, Kumagai K, Urata H, Gondo N, Ideishi M, Arakawa K. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000 101 : 2612 2617.
19. Shinagawa K, Mitamura H, Ogawa S, Nattel S. Effects of inhibiting Na(+)/H(+)-exchange or angiotensin converting enzyme on atrial tachycardia-induced remodeling. Cardiovasc Res 2002 54 : 438 446.
20. Tsai CT, Lai LP, Lin JL, Chiang FT, Hwang JJ, Ritchie MD, Moore JH, et al. Renin-angiotensin system gene polymorphisms and atrial fibrillation. Circulation 2004 109 : 1640 1646.
21. Li D, Shinagawa K, Pang L, Leung TK, Cardin S, Wang Z, Nattel S. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 2001 104 : 2608 2614.
22. Mathew JP, Fontes ML, Tudor IC, Ramsay J, Duke P, Mazer CD, Barash PG, et al. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA 2004 291 : 1720 1729.
23. Ueng KC, Tsai TP, Yu WC, Tsai CF, Lin MC, Chan KC, Chen CY, et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J 2003 24 : 2090 2098.
24. Madrid AH, Bueno MG, Rebollo JM, Marin I, Pena G, Bernal E, Rodriguez A, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: A prospective and randomized study. Circulation 2002 106 : 331 336.
25. Anand K, Mooss AN, Hee TT, Mohiuddin SM. Meta-analysis: Inhibition of renin-angiotensin system prevents new-onset atrial fibrillation. Am Heart J 2006 152 : 217 222.
26. Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, Connolly SJ. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: A meta-analysis. J Am Coll Cardiol 2005 45 : 1832 1839.
27. Okin PM, Wachtell K, Devereux RB, Harris KE, Jern S, Kjeldsen SE, et al. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA 2006 296 : 1242 1248.
28. Lee KW, Everett THt, Rahmutula D, Guerra JM, Wilson E, Ding C, Julius S, et al. Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure. Circulation 2006 114 : 1703 1712.
29. Kato T, Yamashita T, Sekiguchi A, Tsuneda T, Sagara K, Takamura M, Kaneko S, et al. AGEs-RAGE system mediates atrial structural remodeling in the diabetic rat. J Cardiovasc Electrophysiol 2008 19 : 415 420.
30. Bruins P, te Velthuis H, Yazdanbakhsh AP, Jansen PG, van Hardevelt FW, de Beaumont EM, Wildevuur CR, et al. Activation of the complement system during and after cardiopulmonary bypass surgery: Postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation 1997 96 : 3542 3548.
31. Halonen J, Halonen P, Jarvinen O, Taskinen P, Auvinen T, Tarkka M, Hippelainen M, et al. Corticosteroids for the prevention of atrial fibrillation after cardiac surgery: A randomized controlled trial. JAMA 2007 297 : 1562 1570.
32. Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA, Tracy RP, et al. Inflammation as a risk factor for atrial fibrillation. Circulation 2003 108 : 3006 3010.
33. Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA, Bauer JA, et al. C-reactive protein elevation in patients with atrial arrhythmias: Inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001 104 : 2886 2891.
34. Hatzinikolaou-Kotsakou E, Tziakas D, Hotidis A, Stakos D, Floros D, Papanas N, Chalikias G, et al. Relation of C-reactive protein to the first onset and the recurrence rate in lone atrial fibrillation. Am J Cardiol 2006 97 : 659 661.
35. Liu T, Li G, Li L, Korantzopoulos P. Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: A meta-analysis. J Am Coll Cardiol 2007 49 : 1642 1648.
36. Rotter M, Jais P, Vergnes MC, Nurden P, Takahashi Y, Sanders P, Rostock T, et al. Decline in C-reactive protein after successful ablation of long-lasting persistent atrial fibrillation. J Am Coll Cardiol 2006 47 : 1231 1233.
37. Marcus GM, Smith LM, Glidden DV, Wilson E, McCabe JM, Whiteman D, Tseng ZH, et al. Markers of inflammation before and after curative ablation of atrial flutter. Heart Rhythm 2008 5 : 215 221.
38. Kumagai K, Nakashima H, Saku K. The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc Res 2004 62 : 105 111.
39. Shiroshita-Takeshita A, Schram G, Lavoie J, Nattel S. Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation 2004 110 : 2313 2319.
40. Patti G, Chello M, Candura D, Pasceri V, D'Ambrosio A, Covino E, Di Sciascio G. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: Results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation 2006 114 : 1455 1461.
41. Dernellis J, Panaretou M. Effect of C-reactive protein reduction on paroxysmal atrial fibrillation. Am Heart J 2005 150 : 1064.
42. Fauchier L, Pierre B, de Labriolle A, Grimard C, Zannad N, Babuty D. Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2008 51 : 828 835.
43. Dhein S, Michaelis B, Mohr FW. Antiarrhythmic and electrophysiological effects of long-chain omega-3 polyunsaturated fatty acids. Naunyn Schmiedebergs Arch Pharmacol 2005 371 : 202 211.
44. Xiao YF, Ke Q, Wang SY, Auktor K, Yang Y, Wang GK, Morgan JP, et al. Single point mutations affect fatty acid block of human myocardial sodium channel alpha subunit Na+ channels. Proc Natl Acad Sci U S A 2001 98 : 3606 3611.
45. Macleod JC, Macknight AD, Rodrigo GC. The electrical and mechanical response of adult guinea pig and rat ventricular myocytes to omega3 polyunsaturated fatty acids. Eur J Pharmacol 1998 356 : 261 270.
46. Reiffel JA, McDonald A. Antiarrhythmic effects of omega-3 fatty acids. Am J Cardiol 2006 98 : 50i 60i.
47. da Cunha DN, Hamlin RL, Billman GE, Carnes CA. n-3 (omega-3) Polyunsaturated fatty acids prevent acute atrial electrophysiological remodeling. Br J Pharmacol 2007 150 : 281 285.
48. Mozaffarian D, Psaty BM, Rimm EB, Lemaitre RN, Burke GL, Lyles MF, Lefkowitz D, et al. Fish intake and risk of incident atrial fibrillation. Circulation 2004 110 : 368 373.
49. Brouwer IA, Heeringa J, Geleijnse JM, Zock PL, Witteman JC. Intake of very long-chain n-3 fatty acids from fish and incidence of atrial fibrillation. The Rotterdam Study. Am Heart J 2006 151 : 857 862.
50. Calo L, Bianconi L, Colivicchi F, Lamberti F, Loricchio ML, de Ruvo E, Meo A, et al. N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: A randomized, controlled trial. J Am Coll Cardiol 2005 45 : 1723 1728.
51. Biscione F, Totteri A, De Vita A, Lo Bianco F, Altamura G. Effect of omega-3 fatty acids on the prevention of atrial arrhythmias. Ital Heart J Suppl 2005 6 : 53 59.
52. Nodari S. Effects of Polyunsaturated Fatty Acids n-3 (PUFA n-3) in the prophylaxis of atrial fibrillation relapses after external electric cardioversion abstract supplement) Eur Heart J 2006 887.
53. National Institutes of Health, Bethesda, MD, http://clinicaltrials.gov/ ct2/show/NCT00402363?term=om8&rank=1 accessed November 18, 2008 S, Al-Saady N, Camm AJ. 5-Hydroxytryptamine and atrial fibrillation: How significant is this piece in the puzzle? J Cardiovasc Electrophysiol 2003 14 : 209 214.
54. Leftheriotis DI, Theodorakis GN, Poulis D, Flevari PG, Livanis EG, Iliodromitis EK, Papalois A, et al. The effects of 5-HT4 receptor blockade and stimulation, during six hours of atrial fibrillation. Europace 2005 7 : 560 568.
55. Glaxo SmithKline. Annual Report 2004 (Glaxo SmithKline, 2005).
56. Duffy HS, Wit AL. Is there a role for remodeled connexins in AF? No simple answers. J Mol Cell Cardiol 2008 44 : 4 13.
57. Gollob MH, Jones DL, Krahn AD, Danis L, Gong XQ, Shao Q, Liu X, et al. Somatic mutations in the connexin 40 gene (GJA5) in atrial fibrillation. N Engl J Med 2006 354 : 2677 2688.
58. Shiroshita-Takeshita A, Sakabe M, Haugan K, Hennan JK, Nattel S. Model-dependent effects of the gap junction conduction-enhancing antiarrhythmic peptide rotigaptide (ZP123) on experimental atrial fibrillation in dogs. Circulation 2007 115 : 310 318.
59. Guerra JM, Everett THt, Lee KW, Wilson E, Olgin JE. Effects of the gap junction modifier rotigaptide (ZP123) on atrial conduction and vulnerability to atrial fibrillation. Circulation 2006 114 : 110 118.
60. Persson F, Andersson B, Duker G, Jacobson I, Carlsson L. Functional effects of the late sodium current inhibition by AZD7009 and lidocaine in rabbit isolated atrial and ventricular tissue and Purkinje fibre. Eur J Pharmacol 2007 558 : 133 143.
61. Goldstein RN, Khrestian C, Carlsson L, Waldo AL. Azd7009: A new antiarrhythmic drug with predominant effects on the atria effectively terminates and prevents reinduction of atrial fibrillation and flutter in the sterile pericarditis model. J Cardiovasc Electrophysiol 2004 15 : 1444 1450.
62. Fedida D, Orth PM, Chen JY, Lin S, Plouvier B, Jung G, Ezrin AM, et al. The mechanism of atrial antiarrhythmic action of RSD1235. J Cardiovasc Electrophysiol 2005 16 : 1227 1238.
63. Roy D, Pratt CM, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S, Nielsen T, et al. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: A phase 3, randomized, placebo-controlled trial. Circulation 2008 117 : 1518 1525.
64. Kowey PR RD, Pratt CM. Efficacy and safety of vernakalant hydrochloride injection for the treatment of atrial fibrillation after valvular or coronrary artery bypass surgery abstract) Circulation 2007 116 : 2860.
65. Cardiome Pharma Corp., Vancouver, Canada, http://www.cardiome.com/ VernakalantOral.php accessed November 18, 2008 A, Di Diego JM, Zygmunt AC, Belardinelli L, Antzelevitch C. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: Differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation 2007 116 : 1449 1457.
66. Scirica BM, Morrow DA, Hod H, Murphy SA, Belardinelli L, Hedgepeth CM, Molhoek P, et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with nonST-segment elevation acute coronary syndrome: Results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 2007 116 : 1647 1652.
67. Pritchett EL, Page RL, Connolly SJ, Marcello SR, Schnell DJ, Wilkinson WE. Antiarrhythmic effects of azimilide in atrial fibrillation: Efficacy and dose-response. Azimilide Supraventricular Arrhythmia Program 3 (SVA-3) Investigators. J Am Coll Cardiol 2000 36 : 794 802.
68. Pritchett EL, Kowey P, Connolly S, Page RL, Kerr C, Wilkinson WE. Antiarrhythmic efficacy of azimilide in patients with atrial fibrillation. Maintenance of sinus rhythm after conversion to sinus rhythm. Am Heart J 2006 151 : 1043 1049.
69. Kerr CR, Connolly SJ, Kowey P, Page RL, Pritchett EL, Ruda MY, Ruzyllo W, et al. Efficacy of azimilide for the maintenance of sinus rhythm in patients with paroxysmal atrial fibrillation in the presence and absence of structural heart disease. Am J Cardiol 2006 98 : 215 218.
70. Gautier P, Guillemare E, Marion A, Bertrand JP, Tourneur Y, Nisato D. Electrophysiologic characterization of dronedarone in guinea pig ventricular cells. J Cardiovasc Pharmacol 2003 41 : 191 202.
71. Lalevee N, Nargeot J, Barrere-Lemaire S, Gautier P, Richard S. Effects of amiodarone and dronedarone on voltage-dependent sodium current in human cardiomyocytes. J Cardiovasc Electrophysiol 2003 14 : 885 890.
72. Sun W, Sarma JS, Singh BN. Chronic and acute effects of dronedarone on the action potential of rabbit atrial muscle preparations: Comparison with amiodarone. J Cardiovasc Pharmacol 2002 39 : 677 684.
73. Touboul P, Brugada J, Capucci A, Crijns HJ, Edvardsson N, Hohnloser SH. Dronedarone for prevention of atrial fibrillation: A dose-ranging study. Eur Heart J 2003 24 : 1481 1487.
74. Singh BN, Connolly SJ, Crijns HJ, Roy D, Kowey PR, Capucci A, Radzik D, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 2007 357 : 987 999.
75. Davy J. Efficacy and safety of dronedarone for the control of ventricular rate abstract) AHA 2005 Scientific Sessions 2005 : 2737.
76. Sablayrolles S, Le Grand B. Drug evaluation: Dronedarone, a novel non-iodinated anti-arrhythmic agent. Curr Opin Investig Drugs 2006 7 : 842 849.
77. Dale KM, White CM. Dronedarone: An amiodarone analog for the treatment of atrial fibrillation and atrial flutter. Ann Pharmacother 2007 41 : 599 605.
78. Hohnloser S. A placebo-controlled, double-blind, parallel arm trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter (AF/AFL). Heart Rhythm Society 2008 Scientific Sessions San Francisco, CA. May 15, 2008.